Accéder au contenu
Merck

SML0937

Darunavir

≥98% (HPLC), HIV protease inhibitor, powder

Synonyme(s) :

TMC-114, UIC-94017, [(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4- [(4-aminophenyl)sulfonyl- (2-methylpropyl)amino]-3-hydroxy-1-phenyl- butan-2-yl]

Slide 1 of 1
Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

10 MG

124,00 €

50 MG

488,00 €

124,00 €

Vérifier la disponibilité des articles du panier
Demander une commande groupée

A propos de cet article

Formule empirique (notation de Hill) :
C27H37N3O7S
Numéro CAS:
206361-99-1
Poids moléculaire :
547.66
UNSPSC Code:
51111800
PubChem Substance ID:
329825618
NACRES:
NA.77
MDL number:
MFCD09260006

Principaux documents

Voir toute la documentation

Passer à

Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Darunavir, ≥98% (HPLC)

SMILES string

[H][C@]1([C@@H](OC(N[C@@H](CC2=CC=CC=C2)[C@@H](CN(S(C3=CC=C(N)C=C3)(=O)=O)CC(C)C)O)=O)CO4)[C@]4([H])OCC1

InChI

1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

InChI key

CJBJHOAVZSMMDJ-HEXNFIEUSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Catégories apparentées

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article
SML0685SML1883SML2357
Darunavir ≥98% (HPLC)

Sigma-Aldrich

SML0937

Darunavir

Amprenavir ≥98% (HPLC)

Sigma-Aldrich

SML0685

Amprenavir

AR231453 ≥98% (HPLC)

Sigma-Aldrich

SML1883

AR231453

Isavuconazole ≥98% (HPLC)

Sigma-Aldrich

SML2357

Isavuconazole

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

Biochem/physiol Actions

Darunavir has been sanctioned by the food and drug administration (FDA) as the first treatment of drug-resistant human immunodeficiency virus (HIV).[1]
Darunavir is a HIV protease inhibitor; antiretroviral.
Darunavir is a second-generation antiviral HIV protease inhibitor with broad spectrum activity.

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000501707
0000501707
0000313547
0000313547
0000313550

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Joseph J Eron et al.
AIDS (London, England), 32(11), 1431-1442 (2018-04-24)
To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infected adults. Phase-3, randomized, active-controlled, double-blind, international, multicenter, noninferiority study (NCT02431247). Seven hundred and twenty-five participants
Stein Schalkwijk et al.
Clinical pharmacokinetics, 57(6), 705-716 (2017-07-27)
Fetal antiretroviral exposure is usually derived from the cord-to-maternal concentration ratio. This static parameter does not provide information on the pharmacokinetics in utero, limiting the assessment of a fetal exposure-effect relationship. The aim of this study was to incorporate placental
David Wu et al.
Journal of clinical medicine, 9(6) (2020-06-21)
The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus causes severe respiratory symptoms which manifest disproportionately in the elderly. Currently, there are over 6.5 million cases and 380,000 deaths reported. Given the current severity of the
Thomas N Kakuda et al.
Antiviral therapy, 19(6), 597-606 (2014-06-26)
Darunavir requires pharmacokinetic enhancement to increase its bioavailability. Cobicistat is potentially an alternative pharmacokinetic booster to ritonavir. Bioequivalence of a darunavir/cobicistat fixed-dose combination (FDC) versus darunavir and cobicistat co-administered as single agents and the effect of a high-fat meal on
Alper Daskapan et al.
Therapeutic drug monitoring, 41(1), 59-65 (2018-11-30)
Darunavir is a second-generation protease inhibitor and is registered for the treatment of HIV-1 infection. The aim of this study was to develop and validate a darunavir population pharmacokinetic model based on data from daily practice. Data sets were obtained
Afficher tous les articles scientifiques apparentés

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Évaluations

Aucune valeur de notation

Filtres actifs

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique